Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2

Correlations between in vitro potency of polyethylene glycol–protein conjugates and their chromatographic behavior

(2009) Simon Caserman et al.   ANALYTICAL BIOCHEMISTRY

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

Engineered protein scaffolds as next-generation antibody therapeutics

(2009) Michaela Gebauer et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

(2008) Sean P Dineen et al.   BMC CANCER

Targeting Angiogenesis in Renal Cell Carcinoma

(2008) Georgios Lainakis et al.   CURRENT CANCER DRUG TARGETS

VEGFR3: A New Target for Antiangiogenesis Therapy?

(2008) Timothy P. Padera et al.   DEVELOPMENTAL CELL

First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

(2008) Andrea Molckovsky et al.   Journal of Hematology & Oncology

The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics

(2008) C.Simone Fishburn   JOURNAL OF PHARMACEUTICAL SCIENCES

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE